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Familial 
hypercholesterolemia 
(FH) 
• Inherited disorder of cholesterol 
metabolism 
•Monogenic disease 
• Autosomal dominant 
•Heterozygous prevalence of 1/500 
•  Increased cardiovascular risk 
•  WHO recommends FH screening 
 Clinical history 
 Physical signs 
 Biochemical Markers 
 Family history 
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Portuguese FH Study 
(PFHS) 
Mutation
No mutation
37% Use different clinical criteria to 
evaluate if is possible to 
improve the mutation 
detection rate 
 
 
Compare efficacy of the 
application of SBRG and DMP 
criteria to Portuguese índex 
patients with  results of 
molecular study  
AIM 
Mutation detection rate of 37% 
13 years of PFHS  
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Criteria
Biochemical 
measurements
A. TC >290 mg/dL (>7.5 mmol/L) or LCL-C >190 mg/dL
(>4.9 mmol/L) in an adult patient or TC >155 mg/dL
(>4.0 mmol/L) or LDL-C >155mg/dL (>4.0 mmol/L) in
a child patient under 16 years
Physical 
signs
B. Tendon xanthomas in the patient or in a first- or a
second-degree relative of the patient
Family 
history
C. Myocardial infarction before 50 years in a first- or a
second- degree relative or before 60 years in a
first-degree relative of the patient
D. TC >290 mg/dL (>7.5 mmol/L) in a first- or a
second-degree relative of the patient
Molecular 
study
E. Mutation in LDLR gene or in any other gene that is
related with HeFH
Diagnosis:
Definite HeFH  A+B or E
Probable HeFH  A+C or A+D
Criteria Score
Family
history
First-degree relative with premature coronary and
vascular disease
1
Plasma LDL-C>95th centile for age and sex in an adult
relative
1
Plasma LDL-C>95th centile for age and sex in a
first-degree relative <18 years of age
2
Tendon xanthomas or arcus cornealis in a
first-degree relative
2
Personal 
clinical history
Premature coronary artery disease in the patient 2
Premature cerebral or peripheral vascular
disease in the patient
1
Physical
signs
Tendon xanthomas in the patient 6
Arcus cornealis in a patient under 45 years 4
Biochemical 
measurements
Patient with LCL-C >330 mg/dL (>8.5 mmol/L) 8
Patient with LCL-C 250-329mg/dL (6.5-8.4 mmol/L) 5
Patient with LCL-C 190-249 mg/dL (5.0-6.4 mmol/L) 3
Patient with LCL-C 155-189 mg/dL (4.0-4.9 mmol/L) 1
Molecular 
study
Mutation in LDLR gene or in any other gene that is
related with HeFH
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Dutch MEDPED (DMP) criteria for clinical diagnosis of FH 
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Dutch MEDPED (DMP) criteria for clinical diagnosis of FH 
Diagnosis Score
Definite HeFH >8
Probable HeFH 6-8
Possible HeFH 3-5
Methods 
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Sample 
609 index patients already studied by the PFHS 
• 236 children 
• 373 adults 
Classification according to 
criteria for clinical 
diagnosis of FH 
• SBRG criteria 
 
• DMP criteria 
LDLR 
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236 children – 90 with 
mutation (38%) 
• SBRG criteria 
  - Detection rate of 62% in 
probable HeFH 
  - 26 false negative diagnosis 
• DMP criteria 
  - Detection rate of 59% in 
possible/probable/definite HeFH 
  - 21 false negative diagnosis 
133 
103 
119 113 4 
Similar results 
Criteria for clinical 
diagnosis of FH 
• False negative  clinical diagnosis of 
FH is probably due to insuficient data 
or because the phenotype is milder in 
children (no environmental effect) 
• Similar results when índex patients in 
each classification were divided by 
type of mutation  
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373 adults – 136 with mutation 
(36%) 
• SBRG criteria 
  - Detection rate of 54% in 
probable/definite HeFH 
  - 44 false negative diagnosis 
• DMP criteria 
  - Detection rate of 45% in 
possible/probable/definite HeFH 
  - 18 false negative diagnosis 
• False negative  clinical diagnosis of 
FH is probably due to insuficient data 
• Similar results when índex patients 
in each classification were divided by 
type of mutation 
Criteria for clinical 
diagnosis of FH 204 
159 
10 
109 
214 
30 
Similar results 
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Similar results with two criteria for clinical diagnosis of FH that 
misdiagnosed about 35% of the Portuguese índex patients 
 
Combine efforts to construct an international set of criteria in order 
to increase the detection of FH patients. It is necessary to improve 
the specifications of both criteria: 
 DMP •include a specific cut off for children  
  •increase score for first relative with CAD 
  SBRG ●include a diagnosis for probable FH for patients  
  with established CAD 
 
This is a preliminary study that can open new ways to the clinical 
diagnosis of FH and improve the rate of identification of patients 
with high cardiovascular risk 
 
In the future we will perform a new evaluation of both criteria in 
Portuguese índex patients using the new specifications to see if we 
can improve the results 
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